NO20061614L - benzimidazole acetonitriles - Google Patents

benzimidazole acetonitriles

Info

Publication number
NO20061614L
NO20061614L NO20061614A NO20061614A NO20061614L NO 20061614 L NO20061614 L NO 20061614L NO 20061614 A NO20061614 A NO 20061614A NO 20061614 A NO20061614 A NO 20061614A NO 20061614 L NO20061614 L NO 20061614L
Authority
NO
Norway
Prior art keywords
acetonitriles
benzimidazole
group
alkynyl
alkenyl
Prior art date
Application number
NO20061614A
Other languages
Norwegian (no)
Inventor
Jean-Pierre Gotteland
Pascale Gaillard
Matthias Schwarz
Patrick Page
Russell J Thomas
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of NO20061614L publication Critical patent/NO20061614L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Foreliggende oppfinnelse angår benzimidazolacetonitriler så vel som farmasøytiske formuleringer som inneholder slike benzimidazolacetonitriler med formel (I). Nevnte benzimidazolacetonitriler kan brukes for behandling av metabolske lidelser som er kontrollert eller forårsaket av insulinresistens eller hyperglykemi, og som omfatter diabetes II, utilfredsstillende glukosetoleranse, insulinresistens, overvekt og polycystisk eggstokksyndrom (PCOS) (I). Den foreliggende oppfinnelsen angår videre fremgangsmåter for fremstilling av benzimidazolacetonitriler, hvor G er pyrimidinyl, L er en aminogruppe eller en 3-8-leddet heterosykloalkylgruppe som inneholder minst ett heteroatom valgt fra N, O eller S, eller L er en acylaminogruppe; R1 er valgt fra gruppen bestående av hydrogen, sulfonyl, amino, karboksy, aminokarbonyl, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl eller C1-C6-alkoksy, aryl, halogen, cyano eller hydroksy; R2 er valgt fra gruppen bestående av hydrogen, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, eller C1-C6-alkoksy.The present invention relates to benzimidazole acetonitriles as well as pharmaceutical formulations containing such benzimidazole acetonitriles of formula (I). Said benzimidazole acetonitriles can be used to treat metabolic disorders controlled or caused by insulin resistance or hyperglycemia, which include diabetes II, inadequate glucose tolerance, insulin resistance, obesity and polycystic ovarian syndrome (PCOS) (I). The present invention further relates to processes for the preparation of benzimidazole acetonitriles, wherein G is pyrimidinyl, L is an amino group or a 3-8 membered heterocycloalkyl group containing at least one heteroatom selected from N, O or S, or L is an acylamino group; R 1 is selected from the group consisting of hydrogen, sulfonyl, amino, carboxy, aminocarbonyl, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl or C 1 -C 6 alkoxy, aryl, halogen, cyano or hydroxy; R 2 is selected from the group consisting of hydrogen, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, or C 1 -C 6 alkoxy.

NO20061614A 2003-09-12 2006-04-10 benzimidazole acetonitriles NO20061614L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03102741 2003-09-12
PCT/EP2004/052137 WO2005026155A1 (en) 2003-09-12 2004-09-10 Benzimidazole acetonitriles

Publications (1)

Publication Number Publication Date
NO20061614L true NO20061614L (en) 2006-04-10

Family

ID=34306922

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20061614A NO20061614L (en) 2003-09-12 2006-04-10 benzimidazole acetonitriles

Country Status (7)

Country Link
EP (1) EP1667995A1 (en)
JP (1) JP2007505085A (en)
AU (1) AU2004272306A1 (en)
CA (1) CA2534317A1 (en)
IL (1) IL174135A0 (en)
NO (1) NO20061614L (en)
WO (1) WO2005026155A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7713973B2 (en) 2004-10-15 2010-05-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
EP2275095A3 (en) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
EP2377530A3 (en) 2005-10-21 2012-06-20 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
CA2651813A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US20100120717A1 (en) 2006-10-09 2010-05-13 Brown Jason W Kinase inhibitors
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
CN113281309B (en) * 2021-05-17 2022-03-01 深圳市罗湖区人民医院 Chlorpyrifos, carbendazim and atrazine three-in-one detection method

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1110957A1 (en) * 1999-12-24 2001-06-27 Applied Research Systems ARS Holding N.V. Benzazole derivatives and their use as JNK modulators
KR100816769B1 (en) * 2000-09-06 2008-03-26 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 Inhibitors of glycogen synthase kinase 3

Also Published As

Publication number Publication date
EP1667995A1 (en) 2006-06-14
IL174135A0 (en) 2006-08-01
WO2005026155A1 (en) 2005-03-24
AU2004272306A1 (en) 2005-03-24
JP2007505085A (en) 2007-03-08
CA2534317A1 (en) 2005-03-24

Similar Documents

Publication Publication Date Title
NO20061614L (en) benzimidazole acetonitriles
IL174250A0 (en) Use of benzothiazola derivatives for the preparation of medicament
NO20061599L (en) Benzoxazole acetonitriles
NO20091599L (en) Chemical connections
NO20084005L (en) amine derivatives
ATE431345T1 (en) AZABICYCLO-(3,1,0)-HEXANE DERIVATIVES SUITABLE AS MODULATORS OF DOPAMINE D3 RECEPTORS
NO20063761L (en) Sulfonamide derivatives for the treatment of diseases
NO20080789L (en) 1,4-benzothiazepine 1,1-dioxide derivatives, process for their preparation, medicaments containing this compound and its use as a hypolipid
ATE427926T1 (en) CYCLOALKYLAMIN DERIVATIVES
NO20080456L (en) Novel 2,4-dianilinopyrimidine derivatives, their preparation and their use as drugs, pharmaceutical compositions and, in particular, as IKK inhibitors
NO20064412L (en) Condensed heterocycle derivative, medical composition containing the same and medical use thereof
NO20076638L (en) New 8-sulfonylamino-3-amino-substituted chroman or tetrahydronaphthalene derivatives modulating the 5HT6 receptor
EA200870489A1 (en) Piperidinyl substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
NO20091596L (en) Benzoylamino Heterocyclic Compounds as Glucokinase (GLK) Activators
NO20072389L (en) Substituted benzoquinoline derivatives
NO20063865L (en) Heterocyclic substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
EA200970170A1 (en) DERIVATIVES OF 4-TRIMETHYLAMMONIUM-3-AMINOBUTIRATE AND 4-TRIMETHYLPHOSPHONY-3-AMINOBUTIRATE AS CPT INHIBITORS
MY139454A (en) 4-(aminomethyl)-piperidine benzamides as 5ht4-antagonists
NO20092413L (en) Pyrazolanaloger
CY1107097T1 (en) 5HT4-COMPETITIVE BENZAMIDES 4- (AMINOMETHYL) - Piperidine
NO20064806L (en) Formamide derivatives useful as adenoceptor
NO20076676L (en) New 8-sulfonyl-3-amino-substituted chroman or tetrahydronaphthalene derivatives modulating 5HT6 receptor
TH75318A (en) Benzimidazole derivatives (Benzimidazole derivative) and its use
DE602004029888D1 (en) Hydroxycarbonylphenyl substituierte 4-(aminomethyl)-piperidinbenzamide als 5ht4-antagonisten
EA200600059A1 (en) HETEROCYCLIC SUBSTITUTED 4- (AMINOMETHYL) PIPERIDINE BENZAMIDES AS 5-NT Antagonists

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: ONSAGERS AS, POSTBOKS 6963 ST OLAVS PLASS, 0130 OS

FC2A Withdrawal, rejection or dismissal of laid open patent application